Periodontal disease, a chronic inflammatory condition affecting the gums and supporting structures of teeth, is estimated to impact around 19% of the global adult population, with over 1 billion cases worldwide. Despite the availability of current treatment options, such as scaling and root planing, these therapies fail to address the underlying causes or provide long-term relief, highlighting a significant unmet clinical need. The growing focus on regenerative medicine, advanced biomaterials, and targeted therapies is expected to drive pipeline growth, offering hope for more effective treatments and improved patient outcomes in the coming years.
The Periodontal Disease Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into periodontal disease therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for periodontal disease. The periodontal disease report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The periodontal disease pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with periodontal disease treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to periodontal disease.
Periodontal disease is an inflammatory condition that affects the tissues surrounding and supporting the teeth, caused by bacterial infections that lead to gum recession, tooth loss, and bone destruction. It occurs due to poor oral hygiene, smoking, and genetic factors. The condition progresses through stages, from gingivitis to severe periodontitis, causing irreversible damage if untreated.
Periodontal disease treatment focuses on controlling infection and halting disease progression. Conventional treatments include scaling and root planing, along with surgical interventions for severe cases. Emerging therapies target inflammation reduction, tissue regeneration, and bacterial management, aiming to offer more effective, long-lasting solutions.
Severe periodontal disease affects approximately 19% of the global adult population, equating to over 1 billion cases worldwide. In the United States, nearly 50% of adults experience some form of the disease, while in India, the prevalence among adults reaches 51%. This widespread impact underscores the critical need for innovative therapies in the pipeline.
This section of the report covers the analysis of periodontal disease drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase III holds a major share of the total periodontal disease clinical trials.
The drug molecule categories covered under the periodontal disease pipeline analysis include small molecules, biologics, peptide- based therapies, and gene therapies. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for periodontal disease.
The EMR periodontal disease drug report insights include the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in periodontal disease clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for periodontal disease. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of periodontal disease drug candidates.
Colgate Palmolive is sponsoring a Phase III clinical study to evaluate the effect of a toothpaste containing 0.3% chlorhexidine in subjects with established gingivitis, which is early stage of periodontal disease. The objective of this study is to assess the reduction of gingival inflammation, a key factor in periodontal disease progression. The study is expected to be completed by April 2025, with around 80 participants enrolled.
The Phase 2 clinical trial, sponsored by Peking University Third Hospital, focuses on evaluating the efficacy and safety of human dental pulp mesenchymal stem cells (hDP-MSCs) for treating periodontal disease, specifically chronic periodontitis. This randomized, double-blind, placebo-controlled study aims to assess the impact of different administration protocols on patient outcomes. The trial, involving about 204 participants, is expected to be completed by September 2026.
Sponsored by Krishnadevaraya College of Dental Sciences & Hospital, this Phase 1 study aims to evaluate the effectiveness of Bromelain gel following scaling and root planing (SRP). It is expected to be completed in July 2025, with an estimated 36 participants.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Periodontal Disease Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for periodontal disease. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into periodontal disease collaborations, regulatory environments, and potential growth opportunities.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share